# Linnaeus Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/linnaeus-therapeutics

- Industry: Biotechnology
- Headquarters: US
- Website: www.linnaeustx.com
- Total disclosed funding: $12M
- Latest round: Series B (Sep 17, 2019)
- Investors on record: 2

## About

Linnaeus Therapeutics, Inc. is a biotechnology firm focused on developing innovative cancer therapies, particularly targeting metastatic cutaneous melanoma through their lead product, LNS8801, supported by robust clinical data.Linnaeus Therapeutics, Inc. specializes in the research and development of cancer therapies, with a foundation year of 2016 in the United States. The company was founded by Christopher Natale and is headquartered in Haddonfield, New Jersey. It has received a total of USD 12 mn in funding through two deals, with the most recent funding round, Series B, occurring on September 17, 2019, led by Kairos Ventures and including new investor Penn Medicine.Linnaeus Therapeutics, Inc. specializes in the development of innovative cancer therapies, particularly focusing on their lead product, LNS8801. This therapy targets metastatic cutaneous melanoma and is informed by clinical insights from the Ridky lab at the University of Pennsylvania. Their customer base primarily includes healthcare providers and institutions in oncology, as well as patients with various cancer types, including melanoma, pancreatic ductal adenocarcinoma, and non-small cell lung cancer. Operating from Haddonfield, NJ, the company aims to address markets in North America and potentially Europe, contingent on regulatory and market access considerations.Linnaeus Therapeutics generates revenue through partnerships and collaborations within the biotechnology and pharmaceutical sectors, particularly centered on the clinical development of their flagship product, LNS8801. Revenue is primarily realized through co-development agreements or licensing arrangements with research institutions and pharmaceutical companies, which entail milestone payments and royalties on future sales. The company has received Orphan Drug Designation, supporting its financial model by potentially providing market exclusivity and financial incentives, further extending its reach in the oncology sector.Linnaeus Therapeutics, Inc. plans to leverage its recent Series B funding of USD 12 mn raised in September 2019 to enhance the development and launch of new cancer therapies. The company is also strategizing to expand into European markets, pending regulatory approval by 2023, to increase its product accessibility. These initiatives aim to strengthen their pipeline and commercial viability in the competitive oncology landscape.

## Funding rounds

- Series B, Sep 17, 2019, $12M — Penn Medicine, Kairos Ventures
- Series A, Nov 13, 2018 — Kairos Ventures

## Investors

- Kairos Ventures (https://capitalatlas.ai/funds/kairos-ventures) — Series A, Series B
- Penn Medicine — Series B